ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on X

Kidney Week

Please note that you are viewing an archived section from 2023 and some content may be unavailable. To unlock all content for 2023, please visit the archives.

Abstract: TH-PO1046

Clinical Characteristics, Comorbidities, and Management of Patients with CKD: Insights from iCaReMe Global Registry

Session Information

Category: CKD (Non-Dialysis)

  • 2302 CKD (Non-Dialysis): Clinical, Outcomes, and Trials


  • Pollock, Carol A., Kolling Institute of Medical Research, St Leonards, New South Wales, Australia
  • Khunti, Kamlesh, University of Leicester, Leicester, United Kingdom
  • Heerspink, Hiddo Jan L., Department of Clinical Pharmacy and Pharmacology University Medical Center Groningen, Groningen, Netherlands
  • Nicolucci, Antonio, Center for Outcomes Research and Clinical Epidemiology, Pescara, Italy
  • Joshi, Shashank R., Lilavati Hospital & Research Centre), Mumbai, India
  • Fenici, Peter, AstraZeneca Italy, Milan, Italy
  • Goncalves, Susana, AstraZeneca Argentina, Buenos Aires, Argentina
  • Nguyen Cong, Luong, AstraZeneca Vietnam, Ho Chi Minh City, Viet Nam
  • Vasnawala, Hardik, AstraZeneca India, Bangalore, India
  • Hadaoui, Ahmed, AstraZeneca Algeria, Algiers, Algeria

CKD is recognized as a global health concern with an increased prevalence, and attributable morbidity and mortality particularly in low- and middle-income countries where there is a need to better understand clinical characteristics, and risk factors for CKD within the Cardiovascular Renal Metabolic Continuum. iCaReMe registry is an opportunity to fill this knowledge gap by providing a comprehensive global real-world data source on patients’ characteristics, disease management and outcomes. The objective of our analysis is to describe clinical features, major risk factors, and management of CKD patients based on data from the iCaReMe Registry.


iCaReMe Global Registry (NCT03549754) is a multinational, prospective, observational study to assess the management and quality of care of patients with CKD, T2D, HTN, and/or HF. We present baseline cross-sectional descriptive analysis of the CKD cohort enrolled from February 2018 to December 2022.


Overall, 2977 adults with CKD (mean age 60.6 years, 54.6% male) were enrolled in 21 countries* across the six WHO regions**. DKD and HKD were the most common etiologies. HTN, T2D, dyslipidemia, HF were present in 80.2%, 72.1%, 44.1% and 35.3% of patients respectively. Mean UACR was 556.7 mg/g available in 891 (30%) patients and mean eGFR was 46.1ml/min/1.73m2 reported in 2492 (83.7%) patients. ACEi or ARB were prescribed to 37.8% of patients, and 20.6% received an SGLT2i.


Our results highlight opportunities to improve CKD management particularly in patients with CVD multimorbidity and advanced CKD by enhancing the use of albuminuria monitoring and the adoption of evidence-based treatments.


  • Commercial Support – AstraZeneca